First heart attack patient treated in European cardioprotection phase III trial with NeuroVive's CicloMulsion
NeuroVive Pharmaceutical and Hospices Civils de Lyon (HCL) today announced the enrollment and treatment of the first patient in the European multicenter trial…
Apr 19, 2011